Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2018-08-31 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于认购GNC发行的可转换优先股事宜的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of the company's subscription to convertible preferred shares issued by GNC. It mentions approvals and filings with various regulatory bodies and states that the company will continue to disclose information as the matter progresses. The document is short (507 characters) and serves as an update on a capital transaction rather than a full financial report or detailed presentation. It fits the category of Capital/Financing Update (CAP) because it relates to financing activities and capital structure changes.
2018-08-31 Chinese
八届十次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details decisions made by the board regarding relocation plans for various company facilities and authorizations given to management. The document includes voting results and assurances about the accuracy of the announcement. It does not contain financial statements, detailed financial analysis, or comprehensive report content. It is not a full annual or interim report, nor is it a regulatory filing or certification. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management.
2018-08-20 Chinese
八届九次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It reports the approval of the 2018 half-year report and asset impairment provisions by the board of directors. The document is short (587 characters) and states that the full half-year report is disclosed on the Shanghai Stock Exchange website, indicating this document is an announcement of the board's approval rather than the full interim report itself. Therefore, it is not the interim report (IR) but rather a regulatory announcement related to board decisions. The best fitting category is Board/Management Information (MANG) because it announces board meeting resolutions and approvals related to financial reporting.
2018-08-14 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2018 年半年度报告' which translates to '2018 Half-Year Report'. It contains detailed financial data, including revenue, profit, cash flow, and segment analysis for the first half of 2018 (January 1 to June 30, 2018). The document includes sections such as company overview, financial indicators, business summary, management discussion and analysis, and detailed financial statements. The length is substantial (15,000 characters) and the content is comprehensive, not merely an announcement or certification. The presence of actual financial statements and substantive financial data for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. H1 2018
2018-08-14 Chinese
2018年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2018 半年度报告摘要' which translates to '2018 Half-Year Report Summary'. It contains detailed financial data for the first half of 2018, including total assets, net profit, revenue, and other financial metrics. It also includes management discussion and analysis of business operations, industry trends, and future plans. The document is about 5714 characters long, which is sufficient to contain substantive financial data and analysis. It is not merely an announcement or a certification. The content matches the characteristics of an Interim / Quarterly Report, which covers a period shorter than a full fiscal year and includes actual financial statements and management discussion. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report. H1 2018
2018-08-14 Chinese
八届五次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of 哈药集团股份有限公司 regarding the 2018 half-year report. It includes the supervisory board's review and approval of the 2018 half-year report, confirming compliance with laws and regulations, and the accuracy and completeness of the report. The document is short (641 characters) and primarily serves as an official announcement of the supervisory board's resolution and opinion on the half-year report, rather than the report itself. Therefore, it is not the Interim/Quarterly Report (IR) itself but an announcement related to it. Given the nature of the document as a formal resolution announcement, it fits best under Regulatory Filings (RNS), which covers miscellaneous official announcements that do not fit other categories.
2018-08-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.